Theralase Technologies Inc. V.TLT

Alternate Symbol(s): TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc.

<< Previous

Bullboard Posts

Next >>

Post by ScienceFirston May 30, 2022 9:22pm

306 Views

Post# 34718707

BCG to be challenged by TLD-1433

It's obvious that the FDA wants to bring more options to patients than just BCG. And we have a track record that undisputably outpaces BCG alone.

So that's why Breakthrough designation will be granted.

Maintenance Bacillus Calmette-Guerin (BCG) — Maintenance intravesical BCG treatment is generally recommended for patients with high-risk non-muscle invasive bladder cancer (see "Patient education: Bladder cancer diagnosis and staging (Beyond the Basics)"). The benefit of maintenance treatment is that it may further delay recurrence and progression of the cancer.

Although the optimal duration of maintenance treatment is debated, several expert groups recommend that it be given for at least one year. Maintenance BCG is typically given once per week for three weeks at 3, 6, and 12 months after the initial BCG treatment. In some cases, maintenance BCG treatment will be recommended for one year for those at intermediate risk of recurrence and for three years for those at higher risk for recurrence.